Taco John's Introduces Nacho Taco Bravo, A Craveable New Take on a Classic Favorite
CHEYENNE, Wyo., March 04, 2025 (GLOBE NEWSWIRE) -- Continuing its mission to deliver quality and value, Taco John's® latest limited-time menu item will leave guests seeing double – a big deal and big satisfaction – with TWO of the hearty new Nacho Taco Bravo® for just $6.
Taco John's is giving fans more reason to say 'Bravo!' with a bold new twist on a beloved menu staple. The new Nacho Taco Bravo comes with a generous layer of mouthwateringly melty nacho cheese drizzled inside a flour tortilla filled with refried beans and wrapped around a freshly fried, crispy taco shell. Just like the classic Taco Bravo, it's filled with Taco John's signature seasoned 100% North American beef, original taco sauce, fresh lettuce, and all-natural Cheddar cheese.
Guests can try the new Nacho Taco Bravo a la carte ($4.39), snag two for $6, or as part of a combo meal that includes Potato Olés® and a fountain drink. Looking for a little more variety? Try the Nacho Taco Bravo bundle that adds on a Nacho Crunch Burrito and cinnamon sugar Churro for a sweet finish.
'This is the ultimate Taco Bravo experience,' said Brad Bergaus, Taco John's Corporate Chef and Director of Menu Innovation. 'Our warm nacho cheese is like liquid gold – it makes everything craveable, including one of our all-time menu classics. Adding this cheesy, golden layer puts even more to savor between the two shells of the Taco Bravo, so you get the crunch of a freshly fried crispy taco shell with the mmm of a gooey outer tortilla. It's incredible.'
For a limited time, the Nacho Taco Bravo is available at participating Taco John's locations in-store, at the drive-thru, and through the mobile app.
About Taco John's
With nearly 350 restaurants in 22 states, Taco John's is one of America's largest Mexican quick-service restaurant brands. Founded in 1969 in Cheyenne, Wyoming, Taco John's has been serving a made-to-order menu using fresh, high-quality ingredients, seasonings and sauces for more than 55 years. Offering signature specials like Taco Tuesday, savings and special offers for Bigger Bolder Rewards loyalty club members, and beloved originals like Potato Olés®, Taco John's takes pride in bigger. bolder. better. flavors and menu items. Recognized as one of Entrepreneur 's 'Top Food Franchises of 2023' and hailed by QSR Magazine as a 'Top 15 Chain Ready to Contend as Fast Food's Top Players,' Taco John's continues to expand into new territories. For more information, visit TacoJohns.com and follow Taco John's on Facebook, Instagram and TikTok.
Joshua Levitt
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Common Technical Document Training Course: Enhance Skills in CTD Compilation, QbD, Regulatory Compliance, and Global Dossier Strategies (ONLINE EVENT: July 7-8, 2025)
Join our interactive two-day course for an in-depth understanding of CMC management for EU and US applications. . Achieve expert proficiency with lectures, group work, and discussions. Certified CPD: 12 hours. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "The Common Technical Document Training Course" training has been added to offering. This interactive two-day course will provide you with a clear and comprehensive understanding of the regulatory and technical requirements for CMC management of your full and generic application in major markets of the EU and USA. Furthermore, the course examines the requirements for global roll-out of the dossier to ROW regions including LATAM, ASEAN, MENA and CIS territories. You will increase your ability to manage all aspects of the development of the CMC applications after two days of intensive lectures, group work and discussion sessions, covering everything you need to know about compiling the chemistry and pharmacy section of your generic dossier. Skills you will gain include: Effective compilation of the Common Technical Document (CTD) and critical review of documentation Quality by design (QbD), critical attributes and developing new product using the CQA pyramid model Compiling and submitting Module 3 (CTD) of your registration dossier Identifying the extent of content expected by EU and US regulators Achieving the quickest turnaround of your submission Managing the pharmaceutical and quality aspects of your developments and registration dossier in Europe and the US Ensuring right-first-time development Meeting the legal framework and guidelines for the CMC/quality part of the dossier and links to GMP Who Should Attend: Senior analytical chemists Formulation chemists Technical services chemists Registration staff (all levels) Quality managers Quality control directors R&D project managers Certification: CPD: 12 hours for your records Certificate of completion Key Topics Covered: Day 1 What is the CTD? Pharmaceutical medicine and documents Introduction to CTD, ICH and eCTD Introduction to data standards relevant to module 3 (incl. EMA SPOR, ISO-IDMP) The importance of chemistry/manufacturing and controls (CMC) Setting the scene for the module 3 deep-dive Assessment of biologics and why the CMC section for these products is more extensive A deep-dive in Module 3 - examining the content of all sections Module 3.2 for the substances (32S) Module 3.2 for the final products (32P) Appendices and regional information in Module 3 (32A and 32R) Additional data for generics in the US (ANDA tables) Process validation deep-dive (S25 + P35) Comparability across batches (ICH Q5E) Quality-by-Design and Quality Target Product Profile (ICH Q8, Q9 and Q10) Analytical method deep-dive (ICH Q2 and beyond) Process analytical technology Pharmaceutical quality system (ICH Q10) Post-approval maintenance What and why? EU eCTD lifecycle management US eCTD lifecycle management Product lifecycle management (ICH Q12) and established conditions Day 2 Potential scenario for Module 3 EDQM certificate of suitability of monographs of European pharmacopeia (CoS/CEP) Active substance master file (ASMP) US drug master files (DMFs) Basic principles for eCTD authors (incl. focus on global dossier roll-out) Separating content from contexts Applying the right document granularity Lean and structured authoring Trends, developments and future outlook Identification of medicinal products (IDMP) FDA Knowledge-Aided-Structured-Assessment and Structured-Application (FDA-KASA) FDA Pharmaceutical quality/Chemistry manufacturing and control (PQ/CMC) data elements EMA Digital Application Dataset Integration (DADI) project Accumulus synergy - global information exchange platform Summary of Module 3 and what should stand out from the Quality Overall Summary (module 2) Speakers: Andrew Willis Consultant Independent Andrew Willis is an independent consultant providing expert advice and training on global regulatory solutions and pharmaceutical development. Previously, he worked for Catalent Pharma Solutions as VP Regulatory Affairs & Consulting Services. Catalent is the world's leading contract manufacturer and distributor of pharmaceuticals, and he was head of a team of internal and external regulatory affairs consultants. He qualified as a Chemist from the University of Glamorgan, after which he furthered his understanding of pharmaceutical development, working as a research chemist with Parke Davis. He has 10 years manufacturing and analytical experience prior to entering regulatory affairs as a Senior Executive Officer with responsibility for submission of European MAAs and project management of development programs. He currently has a total of 28 years pharmaceutical experience with extensive knowledge in the development and manufacture of sterile, solid oral, inhalation, topical and biotech pharmaceutical products. These experiences have allowed knowledge of many Biotech products requirements with experiences of growth hormones and multiple cancer treatments, including development and clinical registration of the first genetically modified live bacterium for such treatment. He has extensive experience of major European and US regulatory projects, in the clinical and marketing authorisation stages, and has significant experience in coordinating and managing meetings with European and US Health Authorities. Specific experience includes the project management of a large MAA requiring full clinical data, followed by Mutual Recognition of the application in all of the European Concerned Member States. The project recorded successful outcomes in all major markets (26 countries) and was viewed as highly successful by the client, meeting very stringent project more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
The Pharma Mini MBA Training Course: Transforming Learning into Real-World Industry Impacts (ONLINE EVENT: July 9-11, 2025)
Optimize your leadership role in the competitive pharmaceutical industry with the Pharma Mini MBA. This accelerated, three-day course blends practical management tools with industry-specific case studies to enhance skills and strategic thinking. Gain insights into pharma challenges and technology innovations while earning CPD hours. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "The Pharma Mini MBA Training Course" training has been added to offering. This intensive three-day course will help you to translate your learning into new behaviours and improvements in your capability and performance and will work through live issues impacting on the industry and on you directly. The individual and group exercises will focus on pharmaceutical/biopharma/generic MBA case studies, and also on your own challenges and examples. The business school case studies will help give the 'feel' of a full MBA and help you understand more about the strategies used in today's pharmaceutical and associated industries. Working in the highly competitive pharmaceutical industry, with ever-increasing change and pressure, is probably one of the most challenging managerial roles of any industry today. This event has been especially designed to help you transcend these challenges by training you to become equipped to see the bigger picture in all aspects of your role. It will help you build your management skills for the future and prepare you to fulfil your ambitions. The Pharma Mini MBA accelerated management programme is a distillation of the most valuable parts of an MBA, as applied to the pharmaceutical industry. It will provide you with practical management tools to apply in the workplace, as well as giving a real taste of an MBA course with pharmaceutical case studies from business schools. Pharmaceutical industry context - business school pharmaceutical case studies on each module The Pharma Mini MBA is also an invaluable guide to all that is best and most practical on an MBA course - with specific focus on the pharmaceutical sector. It is also of value either to gain the most useful aspects of an MBA or as an MBA taster, providing a foundation of the essential MBA elements to apply directly to your role. The pharmaceutical industry requires employees to focus on successful leadership and business management skills, which this programme is designed to give you. Who Should Attend: A 'must-attend' for professionals in the pharmaceutical/biopharma/medical device/animal health industries wishing to develop their business management skills for more senior levels and beyond mere technical ability. It will also help anyone thinking of studying for an MBA who would like an idea of what is involved. It is particularly beneficial to attend with a colleague to maximise the practical learning. MBA learning style of the programme The Pharma Mini MBA learning style is 'hands-on' rather than academic. The programme is very practical, without being too theoretical, with industry-relevant case studies drawn from business school cases. The course covers the key areas of an MBA and applies these MBA tools and concepts to the pharmaceutical industry, providing you with a firm foundation of the essential MBA thinking and terminology. Three modules will be covered in just three days of interactive workshops to enhance the value of the course and, to minimise your time away from the office, the programme director also sets optional pre- and post-course work. Develop your understanding of the key techniques of an MBA to apply to your work Gain a greater understanding of the pharma industry, its drivers, challenges and opportunities Hear about the latest strategic technology innovations being used and developed in the pharma industry Understand what strategic thinking is and how to use strategy tools Develop your leadership and strategic skills Become more effective in coping with and managing change in the pharma industry Explore the benefits and costs of doing an MBA Take away a Mini MBA toolkit to apply to your job Discuss and learn from real pharma industry case studies Pre-course work (sent out to delegates prior to the course) Diagnostic questionnaire - your strategic competencies Discussions of diagnostic output/other areas of value Certifications: CPD: 18 hours for your records Certificate of completion Key Topics Covered: Day 1 Strategy and strategic challenges in the pharma industry Strategy and strategic thinking and their importance in the pharma industry Strategic analysis, planning and implementation Environmental analysis Understanding the competitive environment Strategic options Applying the MBA toolkit Stakeholders and their expectations in the pharma industry Obtaining the value out of strategy in the pharma industry Day 2 Commercial management and leadership in the pharma industry New product development and the target product profile Portfolio management used in the pharma industry Understanding business performance The business plan Diagnosing specific performance problems Developing strategic alliances and collaborations in the pharma industry Benefits, costs of doing an MBA and the different routes The role of leadership What are the core competencies of effective leaders in pharma? Leadership vs management Leadership style and approaches in the pharma industry Managing innovation in the pharma industry Innovation approaches currently being adopted along the pharma value chain Future innovations in pharma and the life science industries Day 3 Hot topics in market access strategy Leading and implementing pharma strategy and change Leading successful change Diagnosis around change How to create the conditions for successful change Why people resist change and how to manage this Change management including leading a structural reorganisation Creating a team, department and organisation relevant to today's pharma business needs Team formation and development Implementing strategy and change, essentials of planning and managing projects Project management tools and techniques to use in implementing pharma projects Applying key project management techniques to pharma projects Understanding of cultural awareness to work more effectively with pharma colleagues Practical application/review Personal development action plan to apply the learning within your own organisation Revisiting your competency assessment - what has shifted? Recommended further reading Practical application of tools (toolkit) Speakers: Leela Barham Health Economist and Policy Expert Independent (Freelance) BSc (Economics), MSc (Health Economics) Leela Barham is an independent health economist and policy expert working on a freelance basis. This follows 7 years at a specialist economic consulting firm working in a small dedicated health and pharmaceutical team. She has more than 10 years experience in the pharmaceutical industry - both at home and abroad - and has worked for all stakeholders in the health care system ranging from patient organisations, the National Health Service, health insurers, and the pharmaceutical industry. She has particular expertise in public and patient involvement, Patient Access Schemes/risk sharing schemes, the Cancer Drugs Fund, policy on Health Technology Assessment (HTA), and the Pharmaceutical Price Regulation Scheme (PPRS). She regularly writes on hot topics affecting the industry for Pharmaceutical Executive, Pharmaphorum and EyeforPharma and has also written for PharmaTimes, and Pharma Pricing and Reimbursement. She has also had her research published in peer review journals including The Patient and Pharmacoeconomics. Oguz Ozden Strategy Consultant PwC Oguz is a strategy consultant in PwC's Strategy& practice, leading large, complex and international transformations across the Pharma and Life Sciences sector. He has over 10 years of consulting experience in the sector having worked across various functions in Biotech, Pharma and Consumer Health as well as Pharmaceutical Wholesale. Laura Brown Pharmaceutical QA and Training Consultant University of Cardiff Dr Laura Brown MBA, BSc,PhD, is a Pharmaceutical QA and Training Consultant, Course Director for the MSc in Clinical Research, School of Pharmacy at the University of Cardiff. She has more than 20 years' experience of quality assurance in the pharmaceutical industry and has worked for several companies, including GSKs Hoechst Marion Roussel, Farmitalia and Phoenix International. She has a particular expertise in quality assurance including risked based approaches to quality systems, data Integrity and project management in the pharmaceutical industry. She regularly writes on pharmaceutical regulatory issues including "The Planning of International Drug Development", in the Clinical Research Manual, Euromed and the "Impact of Brexit", RQA Journal 2017. For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
26 minutes ago
- Yahoo
Pharmaceuticals and APIs Good Distribution Practices (GMP) Training Course: Maintain Quality and Integrity Throughout the Entire Supply Chain (ONLINE EVENT: July 9-10, 2025)
Ensure pharmaceutical integrity with a thorough understanding of Good Distribution Practice (GDP) standards. This expert-led training course helps pharmaceutical distributors navigate supply chain challenges, mitigate risks, and safeguard product quality. Gain insights into GDP compliance, counterfeit prevention, and cargo security. Completion grants CPD and a certificate. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Good Distribution Practices of Pharmaceuticals and APIs Training Course" training has been added to offering. It is crucial that pharmaceutical products adhere not only to high-quality standards as per Good Manufacturing Practice but also maintain their quality and integrity throughout the entire supply chain, up to the patient. This training course addresses the imperative for pharmaceutical distributors to adhere to GDP guidelines meticulously. Participants will gain thorough understanding of the roles responsible for implementing these practices and the critical junctures within the supply chain where they are most crucial. Discussions will focus on practical strategies for maintaining the quality, potency, integrity, and identity of pharmaceutical products from raw materials through to final distribution, ensuring compliance and safeguarding patient safety. In today's pharmaceutical landscape, ensuring the safe and reliable distribution of medicinal products is more critical than ever. The complexities of the pharmaceutical supply chain, coupled with the rising threat of counterfeit drugs infiltrating legitimate channels, underscore the necessity for robust Good Distribution Practice (GDP) standards. Good Storage and Distribution Practices (GSP, GDP) are paramount throughout the life cycle of pharmaceutical products and Active Pharmaceutical Ingredients (APIs). European regulations state the importance of implementing quality systems, risk management principles, and clearly defined processes to safeguard pharmaceutical integrity. Pharmaceutical distributors must establish comprehensive quality systems that define roles, processes, and risk management strategies to mitigate these challenges effectively. Benefits of attending Gain a comprehensive understanding of international GDP guidelines and regulations Explore supply chain risks and effective mitigation strategies Identify causes and explore solutions for drug shortages Acquire knowledge on cargo security protocols Receive expert guidance on detecting and preventing counterfeit drugs in the supply chain Learn storage and transportation requirements for pharmaceutical products in alignment with current pharmacopoeias Understand risks associated with transporting temperature-sensitive pharmaceuticals Obtain detailed insights into equipment qualification for storage, transport, and distribution Who Should Attend: Responsible persons Quality assurance specialists Quality control officers Regulatory affairs professionals Engineers Supply chain managers Logistics coordinators Warehouse and distribution managers Contracted warehouse and distribution centre operators Certifications: CPD: 12 hours for your records Certificate of completion Key Topics Covered: Day 1 Introduction to GDP and supply chain What is GDP, GSP? Regulatory Guidelines GDP, GSP (EMA, PIC/S, MHRA, TGA, WHO, FDA, EU GMP Annex 11, 15), USP 1079 Industry APIC, IPEC, PDA, IATA, CEIV, ISPE, ASTM, Introduction to the pharmaceutical supply chain How to determine and mitigate the pharmaceutical supply chain risks? What are the main risks available? Should disaster recovery be a requirement? How to implement contingency planning & business continuity? Drug shortages and counterfeiting How to prevent drug shortages? How to detect counterfeiting in legal supply chain? How to manage fake medicines e.g. during the COVID-19 pandemic? Storage of pharmaceuticals and biologics What is the optimum storage condition for pharmaceuticals, biologicals? How to manage time & temperature sensitive pharmaceutical, biological products? What to do when planning to design a cold room? How to qualify warehouse and distribution equipment? What factors must be taken into consideration to execute a temperature mapping study? Developing a Validation Plan Considering areas at risk Developing a protocol Calibration of data loggers Studying duration of the mapping Determining the measuring range Good Documentation Practices Collecting Data Loggers Downloading data Analysing data (21 CFR Part 11, EU GMP Annex 11, GAMP5) Preparing mapping report How to avoid temperature mapping mistakes? Where to locate temperature mapping devices? How to handle temperature & humidity excursions? What is Mean kinetic Temperature (MKT)? Is it necessary for every temperature ranges? Is it globally accepted? Is humidity a mandatory requirement in warehouses and cold rooms? How to choose the best temperature monitoring device? Temperature mapping study Group exercise 1: Risk assessment application to the pharmaceutical supply chain Critique of format Critique of content Workshop: Risk assessment Breakout groups to review and suggest improvement in risk assessment. Group exercise 2: Temperature risk management Critique of format Critique of content Day 2 Active and passive systems How to choose active and passive temperature-controlled systems? Do you think that you know much about dry ice? Does it make sense to start with a Validation Master Plan? Lane qualification & cargo security considerations What is a route /lane qualification? What are the transportation risks? How to ensure security on the road? How is transport validation different from transport verification? What is the main purpose of cloud-based temperature monitoring? What are the pros and cons of road, sea, air transport? Determining air freight and ocean freight challenges GDP for pharmaceuticals Are they known? Are they followed? Are they enforced? GDP for Active Pharmaceutical Ingredients (APIs) Interpretation of API GDP requirements Responsibilities of involved parties What is new for API manufactures? Implementation status Compliance expectations from API manufacturers Data integrity and Good Documentation Practices Data Integrity for temperature-controlled pharmaceuticals Supplier and customer qualification How to qualify a third-party logistics service provider Are you looking for a partner or supplier? Selecting the best 3PLSP How to audit warehouses and 3PLSPs? Regulatory inspections and cases What do the regulatory inspectors expect to see during an inspection? Group exercise 1: Truck qualification plan Critique of format Critique of content Group exercise 2: How to switch from air to ocean transport Critique of format Critique of content Speakers: Mustafa Edik Independent GMP Consultant and Auditor After graduating as a Chemist from university, Mustafa began his 25 year plus career as a Laboratory Supervisor at Bayer, a German Pharmaceutical Company. After 15 years of working as a Quality Assurance Assistant Manager, Laboratory Supervisor, Pharmaceutical Quality Management Systems, and GMP Lead Auditor, he decided to continue his career as a Consultant. He has served the Turkish Atomic Energy Authority (TAEA) as Principal GMP Auditor and Consultant for 6 years. TAEA was audited by the Republic of Turkey Ministry of Health and granted GMP Certificate for 5 Radiopharmaceuticals. This success has won great acclaim from all health authorities and industry. He has prepared and presented various training courses and workshops to more than 8000 individuals from 150 International and local Pharmaceutical, Medical Device, and Cosmetics companies on GMP, GDP and Pharmaceutical Quality Management Systems. He has taken part in several International Pharmaceutical Facility Establishment projects as GMP Consultant and has also set up various Quality Management Systems for Local Pharmaceutical and Medical Device Companies. While he was the Vice President of Quality and Technical Operations at a Quality Academia Training and Consultancy firm, he acquired and converted it into a 100 % Turkish Company. As the only IRCA Certificated Pharmaceutical Quality Management Systems and GMP Lead Auditor in Turkey, he currently conducts API, Excipient, Packaging Materials Suppliers and Manufacturers, Third Party Logistics Service Providers, Sterile and Non-Sterile Manufacturing Facilities Audits according to FDA, EMA, PIC /S, TMMDA, MHRA, TGA Health Canada, and WHO regulations and guidelines. He finished his second university degree in Biopharmaceutical Sciences BSc (Hons) at Atlantic Technological University - Ireland. He is the author of chapter 6 of the book published by PDA named "Good Distribution Practices" and he is preparing his latest book on 'GMP Audits' which will be published by Taylor & Francis in 2023. For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
